The Evolving Epidemiology of Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Strains Isolated from Adults in Crete, Greece, 2009–2016

키워드

참고문헌 (39)

1. Bogaert D, "Streptococcus pneumoniae colonisation: the key to pneumococcal disease", Lancet Infect Dis, 4, pp.144~154 (2004)
2. Musher DM, "Principles and Practice of Infectious Diseases", pp.2623~2642 (2010), Elsevier
3. Marrie TJ, "Effect of age on the manifestations and outcomes of invasive pneumococcal diseases in adults", Am J Med, 131, pp.100~ (2018)
4. Shea KM, "Rates of pneumococcal disease in adults with chronic medical conditions", Open Forum Infect Dis, 1, pp.ofu024~ (2014)
5. Said MA, "Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques", PLoS One, 8, pp.e60273~ (2013)
6. GBD 2015 LRI Collaborators, "Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015", Lancet Infect Dis, 17, pp.1133~1161 (2017)
7. Welte T, "Clinical and economic burden of community-acquired pneumonia among adults in Europe", Thorax, 67, pp.71~79 (2012)
8. Castiglia P, "Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe", Adv Ther, 31, pp.1011~1044 (2014)
9. Klugman KP, "Herd protection induced by pneumococcal conjugate vaccine", Lancet Glob Health, 2, pp.e365~e366 (2014)
10. Huang SS, "Healthcare utilization and cost of pneumococcal disease in the United States", Vaccine, 29, pp.3398~3412 (2011)
11. Maraki S, "Serotype distribution and antimicrobial resistance of adult Streptococcus pneumoniae clinical isolates over the period 2001-2008 in Crete, Greece", Chemotherapy, 56, pp.325~332 (2010)
12. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement, "Clinical Laboratory Standards Institute", CLSI, ~ (2016)
13. Tsaban G, "Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature", Vaccine, 35, pp.2882~2891 (2017)
14. "National Meningitis Reference Laboratory Data 1993–2015" (2015)[URL]
15. Regev-Yochay G, "The herd effects of infant PCV7", PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel, 2017, pp.35, 2449~2456
16. Waight PA, "Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study", Lancet Infect Dis, 15, pp.535~543 (2015)
17. Rodrigo C, "Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia", Eur Respir J, 4, pp.1632~1641 (2015)
18. Menéndez R, "The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study", Vaccine, 35, pp.5264~5270 (2017)
19. España PP, "Differences in the burden of all-cause CAP due to PCV13 serotypes based in the different use of vaccine by regions in Spain (the CAPA study)", 28th European Congress of Clinical Microbiology and Infectious Diseases (2018)
20. "Immunization, Vaccines and Biologicals - Data, statistics and graphics"[URL]
21. Kazmierczak K, "Distribution of Streptococcus pneumoniae serotypes among global population", 27th European Congress of Clinical Microbiology and Infectious Diseases (2017)
22. Kazmierczak K, "Distribution of Streptococcus pneumoniae serotypes among non-sterile isolates from adults 18 years and older in Europe and the United States, 2014-2015", 27th European Congress of Clinical Microbiology and Infectious Diseases (2017)
23. Horácio AN, "Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012-2014) despite continued reductions in other 13-valent conjugate vaccine serotypes", Front Microbiol, 7, pp.1616~ (2016)
24. Corcoran M, "The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?", Epidemiol Infect, 145, pp.2390~2399 (2017)
25. van der Linden M, "Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany", PLoS One, 10, pp.e0131494~ (2015)
26. Izurieta P, "Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution", Expert Rev Vaccines, 17, pp.479~493 (2018)
27. Feikin DR, "Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites", PLoS Med, 10, pp.e1001517~ (2013)
28. Hausdorff WP, "Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement", Hum Vaccin Immunother, 12, pp.358~374 (2016)
29. Moore MR, "Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance", Lancet Infect Dis, 15, pp.301~309 (2015)
30. Hays C, "Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children", Eur J Clin Microbiol Infect Dis, 36, pp.831~838 (2017)
31. Falcó V, "The spectrum of invasive pneumococcal disease in adults in the XXI century", Clin Pulm Med, 20, pp.214~220 (2013)
32. Dagan R, "Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae", J Infect Dis, 211, pp.1144~1153 (2015)
33. Woodhead M, "Guidelines for the management of adult lower respiratory tract infections--full version", Clin Microbiol Infect, 17(Suppl 6), pp.E1~E59 (2011)
34. Goossens H, "Outpatient antibiotic use in Europe and association with resistance: a cross-national database study", Lancet, 365, pp.579~587 (2005)
35. Imöhl M, "Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany", Int J Med Microbiol, 305, pp.776~783 (2015)
36. Mendes RE, "Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine", Diagn Microbiol Infect Dis, 80, pp.19~25 (2014)
37. Hauser C, "Serotype", serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014, 2016, pp.21(21), ~
38. Soeters HM, "Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease", Antimicrob Agents Chemother, 56, pp.1602~1605 (2012)
39. Cornick JE, "Genomic identification of a novel co-trimoxazole resistance genotype and its prevalence amongst Streptococcus pneumoniae in Malawi", J Antimicrob Chemother, 69, pp.368~374 (2014)

관련 논문AI추천